The short answer
Review kava with the prescriber before adding it to amoxapine. Kava guidance cautions against combining it with sedating substances.
What this answer covers
Oral Piper methysticum; extract, amount and other sedatives are relevant.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- amoxapine
Why the precaution is relevant
NCCIH advises against kava with sedative substances. Amoxapine can affect alertness, so review the actual product and other sedating medicines before adding it.
A reassuring study has limits
A small study did not find impaired driving from its kava preparation compared with placebo. Oxazepam was a separate comparator, and the treatments were not combined.
Check the complete extract label
Different kava extracts and blends need separate assessment. A few hours between doses has not been shown to prevent combined impairment.
Watch for impaired alertness
Amoxapine can affect alertness and coordination. Avoid driving if affected and contact the prescriber if added sleepiness, confusion or unsteadiness appears after a new product. Severe confusion, fainting or inability to wake needs urgent assessment.
Evidence and practical considerations
Side effects & toxicity
Conditional alertness review is supported by product guidance and medication effects; exact pair-specific risk is unmeasured.
- Exact scope
- Oral Piper methysticum; extract, amount and other sedatives are relevant. with Exact oral amoxapine tablets. RxNorm IN722, exact oral amoxapine tablets. Active hydroxy metabolites and dopamine-receptor effects do not make it identical to other antidepressants or antipsychotics.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- A separate-dose driving study with oxazepam does not test this antidepressant combination. No protective spacing interval.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral amoxapine.
Label describes a mild sedative component, dopamine-blocking and neuroleptic malignant syndrome concerns, and active metabolites. It does not explicitly name serotonin syndrome or the requested supplements.
How this applies: RxNorm IN722, exact oral amoxapine tablets. Active hydroxy metabolites and dopamine-receptor effects do not make it identical to other antidepressants or antipsychotics.
No universal supplement interval, event rate or preparation equivalence established.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific original evidence; no untested antidepressant or route transfer.
Not a amoxapine study. Intrinsic liver risk does not establish added amoxapine hepatotoxicity; preparation and co-exposure vary.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty-two adults in a randomized crossover driving study.
Medicinal-dose kava did not significantly impair driving outcomes; oxazepam impaired some outcomes.
How this applies: Preparation-specific original evidence; no untested antidepressant or route transfer.
Not combined administration or evidence that all kava preparations lack impairment.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: 40b12bd8cea055e9
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.